<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668145</url>
  </required_header>
  <id_info>
    <org_study_id>KY20172050-1</org_study_id>
    <nct_id>NCT03668145</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis</brief_title>
  <official_title>Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis, a Randomized Double-blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ursodeoxycholic acid is the mainstay treatment medicine for primary biliary cholangitis(PBC).
      About 1/3 of the patients do not respond to UDCA, which is defined as refractory PBC.
      Mesenchymal stem cells (MSC) has been reported to improve the outcomes of PBC patients.
      Randomization controlled studies are needed to confirm the long term effect of MSC treatment
      for refractory PBC. This study aimed to investigate the safety and efficacy of mesenchymal
      stem cells in PBC patients that do not respond to UDCA treatment. This study is an
      double-blind multicenter randomized and placebo-controlled study. Patients with with
      refractory PBC will be randomly assigned to receive MSC treatment plus UDCA or UDCA alone
      (control). Three times of MSC infusion (0.1-1x10E6 cells/kg body weight) via peripheral vein
      will be given to the experimental group (once in 4 weeks). The primary outcome is absolute
      change in alkaline phosphatase. Secondary outcomes are changes of other liver function
      indices such as ALT TBIL AST GGT, improve of symptoms and liver histology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization will be blinded to participant, care provider, investigator and outcome assessors.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of alkaline phosphatase (ALP)</measure>
    <time_frame>1 year</time_frame>
    <description>The absolute value change of ALP after 1 year of the initial stem cell treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of other liver function indices</measure>
    <time_frame>1 year</time_frame>
    <description>The absolute value change of total bilirubin, ALT, AST, GGT after initial stem cell treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of liver histology</measure>
    <time_frame>1 year</time_frame>
    <description>histological scores assessed by liver biopsy at baseline and after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MSC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mesenchymal stem cell transplantation or placebo infusion via peripheral vein</intervention_name>
    <description>0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points</description>
    <arm_group_label>MSC group</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. informed consent

          2. Age between 18-70 years old

          3. BMI between 17-28

          4. Meeting at least 2 of the 3 criteria: (1) positive for anti-mitochondial antibody
             (AMA)；(2) Elevated ALP or GGT；(3) PBC diagnosis confirmed by liver biopsy

          5. Serum ALP &gt;/=1.67 ULN after at leat 6 months treatment with UDCA 1(3-17mg/kg/day) -

        Exclusion Criteria:

          1. Pregnancy, breast-feeding females

          2. Use of liver-toxic drugs over 2 week within 6 months prior to recruitment；

          3. refractory variceal bleeding, uncontrolled hepatoencephalopathy or uncontrolled
             ascites.

          4. Acute of chronic kidney failure.

          5. Commodities with other liver diseases such as viral hepatitis, alcoholic liver
             disease, auto-immune hepatitis or liver cancer

          6. Severe cardiovascular disease；

          7. liver transplantation listed patients；

          8. ALT/AST over 5xULN，or total bilirubin &gt;85umol/l

          9. anticipated need for liver transplantation within 1 year according to mayo risk score

         10. Other candidates who are judged to be not applicable to this study by doctors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Han, MD</last_name>
    <phone>862984771539</phone>
    <email>guochc@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changcun Guo</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changcun Guo</last_name>
      <phone>13991900180</phone>
      <email>guochc@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Han Ying</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Primary Biliary Cirrhosis (now termed as primary biliary cholangitis), mesenchymal stem cell,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The data will be available after the completion of the study and before publications for 1 year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

